485 related articles for article (PubMed ID: 17973928)
1. Effects of liver fibrosis on verapamil pharmacokinetics in rats.
Chen M; Xu D; Hu XL; Wang H
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):287-94. PubMed ID: 17973928
[TBL] [Abstract][Full Text] [Related]
2. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin.
Hong SP; Chang KS; Koh YY; Choi DH; Choi JS
Arch Pharm Res; 2009 Oct; 32(10):1447-52. PubMed ID: 19898809
[TBL] [Abstract][Full Text] [Related]
3. Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats.
Chung JH; Choi DH; Choi JS
Biopharm Drug Dispos; 2009 Mar; 30(2):90-3. PubMed ID: 19226653
[TBL] [Abstract][Full Text] [Related]
4. Establishment of rat precision-cut fibrotic liver slice technique and its application in verapamil metabolism.
Guo Y; Wang H; Zhang C
Clin Exp Pharmacol Physiol; 2007; 34(5-6):406-13. PubMed ID: 17439408
[TBL] [Abstract][Full Text] [Related]
5. Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in rats.
Li C; Li X; Choi JS
Arch Pharm Res; 2009 Jan; 32(1):133-8. PubMed ID: 19183886
[TBL] [Abstract][Full Text] [Related]
6. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD
Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
[TBL] [Abstract][Full Text] [Related]
7. Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells.
Ikemura K; Urano K; Matsuda H; Mizutani H; Iwamoto T; Okuda M
J Pharmacol Exp Ther; 2009 Jan; 328(1):249-55. PubMed ID: 18842703
[TBL] [Abstract][Full Text] [Related]
8. Enhanced bioavailability of verapamil after oral administration with hesperidin in rats.
Piao YJ; Choi JS
Arch Pharm Res; 2008 Apr; 31(4):518-22. PubMed ID: 18449511
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.
Hirunpanich V; Murakoso K; Sato H
Int J Pharm; 2008 Mar; 351(1-2):133-43. PubMed ID: 18082981
[TBL] [Abstract][Full Text] [Related]
10. Effects of hepatic fibrosis on ofloxacin pharmacokinetics in rats.
Wang H; Liao ZX; Chen M; Hu XL
Pharmacol Res; 2006 Jan; 53(1):28-34. PubMed ID: 16182555
[TBL] [Abstract][Full Text] [Related]
11. Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits.
Kim HJ; Choi JS
Biopharm Drug Dispos; 2005 Oct; 26(7):295-300. PubMed ID: 16013069
[TBL] [Abstract][Full Text] [Related]
12. Effects of morin on the pharmacokinetics of nicardipine after oral and intravenous administration of nicardipine in rats.
Piao YJ; Choi JS
J Pharm Pharmacol; 2008 May; 60(5):625-9. PubMed ID: 18416939
[TBL] [Abstract][Full Text] [Related]
13. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats.
Zhang W; Tan TM; Lim LY
Drug Metab Dispos; 2007 Jan; 35(1):110-5. PubMed ID: 17050652
[TBL] [Abstract][Full Text] [Related]
14. Effect of atorvastatin on the intravenous and oral pharmacokinetics of verapamil in rats.
Choi DH; Chang KS; Hong SP; Choi JS; Han HK
Biopharm Drug Dispos; 2008 Jan; 29(1):45-50. PubMed ID: 17941000
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
[TBL] [Abstract][Full Text] [Related]
16. Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats.
Hu N; Xie S; Liu L; Wang X; Pan X; Chen G; Zhang L; Liu H; Liu X; Liu X; Xie L; Wang G
Drug Metab Dispos; 2011 Mar; 39(3):419-25. PubMed ID: 21135265
[TBL] [Abstract][Full Text] [Related]
17. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
18. Effects of oral epigallocatechin gallate on the pharmacokinetics of nicardipine in rats.
Choi JS; Burm JP
Arch Pharm Res; 2009 Dec; 32(12):1721-5. PubMed ID: 20162400
[TBL] [Abstract][Full Text] [Related]
19. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats.
Zhang Y; Hsieh Y; Izumi T; Lin ET; Benet LZ
J Pharmacol Exp Ther; 1998 Oct; 287(1):246-52. PubMed ID: 9765344
[TBL] [Abstract][Full Text] [Related]
20. Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine.
Saitoh H; Saikachi Y; Kobayashi M; Yamaguchi M; Oda M; Yuhki Y; Achiwa K; Tadano K; Takahashi Y; Aungst BJ
Eur J Pharm Sci; 2006 May; 28(1-2):34-42. PubMed ID: 16457995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]